Cash/Burn From Filing For Period: 

GTHX

G1 Therapeutics

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer.

Cash

$299.9M

Burn Rate

$32.4M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Trilaciclib

Metastatic Colarectal Cancer

Phase 3 Initiation

2H '20

Trilaciclib

Breast Cancer

Phase 2

2H '20

Rintodestrant (mono)

ER+, HER2- BC

Phase 2 Update

2H '20

Rintodestrant (+ palbociclib)

ER+, HER2- BC

Phase 2

2H '20

Lerociclib (+ fulvestrant)

ER+, HER2- BC

Late-Early Stage

2H '20

Lerociclib (+ Tagrisso)

NSCLC

Late-Early Stage

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon